Contribution: Industrial Research Assistance Program – Contributions to Firms
HyperMabs Inc.
$2,282,176.00
COVID-19-Treatment for lung injury
FY 2020-21 · 2021-02-01
Summary
FB100 is a novel treatment for COVID-19 survivors with lung fibrosis. This project will focus on providing preclinical proof-of concept results showing antifibrotic efficacy and tolerability in relevant animal models. In addition, the project will allow HyperMabs to initiate critical manufacturing work that will support the preclinical studies a well as product characterization and release. This project represents important steps of the full non-clinical FB100 development program which will lead to clinical trials in early 2022.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Toronto|Toronto, Ontario, Canada
Recipient Type
For-profit organization
Business Number
704342872
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2021-02-01 | 2020-21 | $1,995,126.00 |
| 1 | 2021-02-01 | 2020-21 | $1,995,126.00 |
| 2 | 2021-02-01 | 2020-21 | $1,995,126.00 |
| 3 | 2021-02-01 | 2020-21 | $2,282,176.00 |
| 4 | 2021-02-01 | 2020-21 | $2,282,176.00 |
| 5 | 2021-02-01 | 2020-21 | $2,282,176.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 92 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 92 jours.
Agreement End Date
2023-05-31
Agreement Number
966019
Agreement Start Date
2021-02-01
Agreement Title
COVID-19-Treatment for lung injury
Agreement Title (French)
COVID-19 - Traitement des lésions pulmonaires
Agreement Type
Contribution
Agreement Value
$2,282,176.00
Amendment Date
2022-12-08
Amendment Number
5
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
FB100 is a novel treatment for COVID-19 survivors with lung fibrosis. This project will focus on providing preclinical proof-of concept results showing antifibrotic efficacy and tolerability in relevant animal models. In addition, the project will allow HyperMabs to initiate critical manufacturing work that will support the preclinical studies a well as product characterization and release. This project represents important steps of the full non-clinical FB100 development program which will lead to clinical trials in early 2022.
Description (French)
Le FB100 est un nouveau traitement pour les survivants de la COVID-19 atteints de fibrose pulmonaire. Ce projet se concentrera sur la fourniture de résultats précliniques de preuve de concept montrant l'efficacité et la tolérabilité antifibrotique dans des modèles animaux pertinents. De plus, le projet permettra à HyperMabs d'initier des travaux de fabrication cruciaux qui soutiendront les études précliniques ainsi que la caractérisation et la libération du produit. Ce projet représente des étapes importantes du programme complet de la mise au point non clinique du FB100 qui conduira à des essais cliniques au début de l'année 2022.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Toronto Centre
Federal Riding (French)
Toronto-Centre
Federal Riding Number
35108
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
704342872
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
HyperMabs Inc.
Recipient Postal Code
M5L 1A9
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2020-2021-Q4-966019
